Table 2.
Risk-benefit of rotavirus vaccination on rotavirus hospitalizations and deaths and associated intussusception risk for one vaccinated birth cohort to age 5 years, multiple countries. While some of these data were not discussed in the meeting, they may help to provide context around the broader issue of intussusception.
| Country [ref] | Vaccine evaluated | Vaccine dose(s) | Overall attributable risk (excess IS cases per 100,000 vaccinated infants) | Rotavirus outcomes averted | IS outcomes caused |
|---|---|---|---|---|---|
| Mexico 23 | RV1 | Dose 1 only | 2.0–3.7 | Hospitalizations: 11,551 | Hospitalizations: 41 |
| Deaths: 663 | Deaths: 2 | ||||
| Brazil 23 | RV1 | Dose 2 only | 1.5 | Hospitalizations: 69,572 | Hospitalizations: 55 |
| Deaths: 640 | Deaths: 3 | ||||
| Australia 50 | RV1 | Doses 1 and 2 | 4.3 | Hospitalizations: 6528 | Hospitalizations: 14 |
| Deaths: Not reported | Deaths: Not reported | ||||
| RV5 | Doses 1 and 2 | 7.0 | |||
| US 27,28 | RV1 | Doses 1 and 2 | 5.3 | Hospitalizations: 53,444 | Hospitalizations: 35–166 |
| Dose 2 only | 7.3 | Deaths: 14 | Deaths: 0.1–0.5 | ||
| RV5 | Dose 1 only | 0.7–1.5 | NA | NA |
IS = intussusception